Home » Abbott Molecular Receives EUA for Monkeypox Test
Abbott Molecular Receives EUA for Monkeypox Test
Abbott Molecular has received Emergency Use Authorization (EUA) from the FDA for its Alinity m MPXV laboratory-based monkeypox test.
The EUA approves the real-time polymerase chain reaction test for qualitative detection of DNA from monkeypox virus in human lesion swab specimens — swabs of acute pustular or vesicular rash.
The Alinity m MPXV assay is designed to be used with the company’s Alinity m system or other authorized instruments. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 that meet the requirements to perform moderate or high complexity tests.
Upcoming Events
-
07May
-
14May
-
30May